SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Enveric Biosciences, Inc. – ‘S-4/A’ on 8/12/20 – ‘EX-99.2’

On:  Wednesday, 8/12/20, at 5:14pm ET   ·   Accession #:  1493152-20-15374   ·   File #:  333-238742

Previous ‘S-4’:  ‘S-4’ on 5/28/20   ·   Next:  ‘S-4/A’ on 9/17/20   ·   Latest:  ‘S-4/A’ on 8/4/21   ·   25 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/12/20  AMERI Holdings, Inc.              S-4/A                113:17M                                    M2 Compliance LLC/FA

Pre-Effective Amendment to Registration Statement – Securities for a Merger   —   Form S-4   —   SA’33
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration Statement   HTML   5.25M 
                - Securities for a Merger                                        
 2: EX-23.4     Consent of Expert or Counsel                        HTML     29K 
 3: EX-23.5     Consent of Expert or Counsel                        HTML     29K 
 4: EX-99.2     Miscellaneous Exhibit                               HTML     30K 
 5: EX-99.3     Miscellaneous Exhibit                               HTML     31K 
 6: EX-99.4     Miscellaneous Exhibit                               HTML     31K 
 7: EX-99.5     Miscellaneous Exhibit                               HTML     31K 
 8: EX-99.6     Miscellaneous Exhibit                               HTML     31K 
 9: EX-99.7     Miscellaneous Exhibit                               HTML     31K 
16: R1          Document and Entity Information                     HTML     43K 
17: R2          Condensed Consolidated Balance Sheets               HTML    137K 
18: R3          Condensed Consolidated Balance Sheets               HTML     47K 
                (Parenthetical)                                                  
19: R4          Condensed Consolidated Statements of Operations     HTML    144K 
                and Comprehensive Income (Loss)                                  
20: R5          Consolidated Statement of Changes in Stockholders'  HTML    116K 
                Equity                                                           
21: R6          Condensed Consolidated Statements of Cash Flows     HTML    113K 
22: R7          Description of Business                             HTML     39K 
23: R8          Summary of Significant Accounting Policies          HTML     93K 
24: R9          Basis of Presentation                               HTML     36K 
25: R10         Equity Transactions                                 HTML     50K 
26: R11         Business Combinations                               HTML     89K 
27: R12         Revenue Recognition                                 HTML     41K 
28: R13         Intangible Assets                                   HTML     45K 
29: R14         Goodwill                                            HTML     37K 
30: R15         Share-Based Compensation                            HTML     34K 
31: R16         Equity Compensation Plans                           HTML     67K 
32: R17         Warrants Outstanding                                HTML     46K 
33: R18         Earnings (Loss) Per Share                           HTML     54K 
34: R19         Incentive Plan Items                                HTML     31K 
35: R20         Bank Debt                                           HTML     34K 
36: R21         Debt                                                HTML     42K 
37: R22         Accrued Expenses and Other Current Liabilities      HTML     35K 
38: R23         Employee Benefit Plan                               HTML     31K 
39: R24         Income Taxes                                        HTML     44K 
40: R25         Leases                                              HTML     46K 
41: R26         Convertible Notes                                   HTML     34K 
42: R27         Commitments and Contingencies                       HTML     48K 
43: R28         Fair Value Measurement                              HTML     53K 
44: R29         Revision of Prior Year Financial Statements         HTML    102K 
45: R30         Preferred Stock                                     HTML     32K 
46: R31         Secured Note                                        HTML     32K 
47: R32         Subsequent Events                                   HTML     63K 
48: R33         Summary of Significant Accounting Policies          HTML    147K 
                (Policies)                                                       
49: R34         Summary of Significant Accounting Policies          HTML     37K 
                (Tables)                                                         
50: R35         Business Combinations (Tables)                      HTML     62K 
51: R36         Earnings (Loss) Per Share (Tables)                  HTML     49K 
52: R37         Commitments and Contingencies (Tables)              HTML     60K 
53: R38         Warrants Outstanding (Tables)                       HTML     48K 
54: R39         Intangible Assets (Tables)                          HTML     45K 
55: R40         Goodwill (Tables)                                   HTML     35K 
56: R41         Equity Compensation Plans (Tables)                  HTML     66K 
57: R42         Debt (Tables)                                       HTML     35K 
58: R43         Accrued Expenses and Other Current Liabilities      HTML     34K 
                (Tables)                                                         
59: R44         Income Taxes (Tables)                               HTML     38K 
60: R45         Leases (Tables)                                     HTML     60K 
61: R46         Fair Value Measurement (Tables)                     HTML     47K 
62: R47         Revision of Prior Year Financial Statements         HTML     99K 
                (Tables)                                                         
63: R48         Description of Business (Details Narrative)         HTML     31K 
64: R49         Description of Business (Details Narrative) (10-K)  HTML     55K 
65: R50         Summary of Significant Accounting Policies          HTML     43K 
                (Details Narrative) (10-K)                                       
66: R51         Summary of Significant Accounting Policies -        HTML     48K 
                Schedule of Disaggregation of Revenue (Details)                  
67: R52         Equity Transactions (Details Narrative) (10-K)      HTML    117K 
68: R53         Business Combinations (Details Narrative)           HTML     69K 
69: R54         Business Combinations (Details Narrative) (10-K)    HTML    115K 
70: R55         Business Combinations - Summary of Foregoing        HTML     83K 
                Acquisitions (Details)                                           
71: R56         Intangible Assets (Details Narrative)               HTML     32K 
72: R57         Intangible Assets (Details Narrative) (10-K)        HTML     37K 
73: R58         Intangible Assets - Schedule of Components of       HTML     39K 
                Intangible Assets (Details) (10-K)                               
74: R59         Intangible Assets - Schedule of Future              HTML     38K 
                Amortization of Intangible Assets (Details) (10-K)               
75: R60         Goodwill (Details Narrative)                        HTML     32K 
76: R61         Goodwill (Details Narrative) (10-K)                 HTML     32K 
77: R62         Goodwill - Schedule of Goodwill (Details) (10-K)    HTML     35K 
78: R63         Share-Based Compensation (Details Narrative)        HTML     37K 
                (10-K)                                                           
79: R64         Equity Compensation Plans (Details Narrative)       HTML     38K 
                (10-K)                                                           
80: R65         Equity Compensation Plans - Schedule of Option      HTML     72K 
                Activity (Details) (10-K)                                        
81: R66         Earnings (Loss) Per Share - Schedule of Earnings    HTML     65K 
                Per Share Basic and Diluted (Details)                            
82: R67         Incentive Plan Items (Details Narrative)            HTML     31K 
83: R68         Bank Debt (Details Narrative)                       HTML     45K 
84: R69         Debt (Details Narrative) (10-K)                     HTML     75K 
85: R70         Debt - Schedule of Short Term Debt (10-K)           HTML     37K 
                (Details)                                                        
86: R71         Accrued Expenses and Other Current Liabilities -    HTML     44K 
                Schedule of Accrued Expenses and Other Liabilities               
                (Details) (10-K)                                                 
87: R72         Employee Benefit Plan (Details Narrative) (10-K)    HTML     36K 
88: R73         Income Taxes (Details Narrative) (10-K)             HTML     36K 
89: R74         Income Taxes - Schedule of Provision for Income     HTML     52K 
                Tax (10-K) (Details)                                             
90: R75         Convertible Notes (Details Narrative)               HTML     53K 
91: R76         Commitments and Contingencies (Details Narrative)   HTML     39K 
92: R77         Commitments and Contingencies - Schedule of         HTML     35K 
                Components of Lease Expense (Details)                            
93: R78         Commitments and Contingencies - Schedule of         HTML     38K 
                Supplemental Balance Sheet Information Related to                
                Leases (Details)                                                 
94: R79         Commitments and Contingencies - Schedule of         HTML     39K 
                Supplemental Cash Flow and Other Information                     
                Related to Leases (Details)                                      
95: R80         Commitments and Contingencies - Schedule of         HTML     49K 
                Maturity Payments of Operating Leases (Details)                  
96: R81         Warrants Outstanding - Schedule of Warrant          HTML     45K 
                Outstanding (Details)                                            
97: R82         Warrants Outstanding - Schedule of Warrants         HTML     52K 
                Activity (Details) (10-K)                                        
98: R83         Preferred Stock (Details Narrative)                 HTML     39K 
99: R84         Secured Note (Details Narrative)                    HTML     35K 
100: R85         Leases (Details Narrative) (10-K)                   HTML     34K  
101: R86         Leases - Schedule of Components of Lease Expense    HTML     35K  
                (Details) (10-K)                                                 
102: R87         Leases - Schedule of Supplemental Balance Sheet     HTML     38K  
                Information Related to Leases (Details) (10-K)                   
103: R88         Leases - Schedule of Supplemental Cash Flow and     HTML     39K  
                Other Information Related to Leases (Details)                    
                (10-K)                                                           
104: R89         Leases - Schedule of Maturity Payments of           HTML     44K  
                Operating Leases (Details) (10-K)                                
105: R90         Fair Value Measurement - Schedule of Financial      HTML     40K  
                Assets Measured at Fair Value (10-K) (Details)                   
106: R91         Fair Value Measurement - Schedule of Fair Value     HTML     39K  
                Change in Levels (10-K) (Details)                                
107: R92         Revision of Prior Year Financial Statements -       HTML    133K  
                Schedule of Consolidated Financial Statements                    
                Previously (Details)                                             
108: R93         Revision of Prior Year Financial Statements -       HTML    138K  
                Schedule of Consolidated Financial Statements                    
                Previously (Details) (10-K)                                      
109: R94         Subsequent Events (Details Narrative)               HTML     55K  
110: R95         Leases - Schedule of Supplemental Cash Flow and     HTML     39K  
                Other Information Related to Leases (Details)                    
112: XML         IDEA XML File -- Filing Summary                      XML    205K  
111: EXCEL       IDEA Workbook of Financial Reports                  XLSX    151K  
10: EX-101.INS  XBRL Instance -- amrh-20200331                       XML   2.20M 
12: EX-101.CAL  XBRL Calculations -- amrh-20200331_cal               XML    211K 
13: EX-101.DEF  XBRL Definitions -- amrh-20200331_def                XML    644K 
14: EX-101.LAB  XBRL Labels -- amrh-20200331_lab                     XML   1.16M 
15: EX-101.PRE  XBRL Presentations -- amrh-20200331_pre              XML    993K 
11: EX-101.SCH  XBRL Schema -- amrh-20200331                         XSD    235K 
113: ZIP         XBRL Zipped Folder -- 0001493152-20-015374-xbrl      Zip    203K  


‘EX-99.2’   —   Miscellaneous Exhibit


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 99.2

 

 

August 12th, 2020

 

The Board of Directors

Ameri Holdings, Inc.

5000 Research Court
Suite 750
Suwanee, GA 30024

 

Board of Directors

 

Members of the Board:

 

We hereby consent to the inclusion of our opinion letters, dated August 7, 2020 to the Board of Directors of Ameri Holdings, Inc (“Ameri”) in the registration statement on Form S-4 being filed on August 12, 2020 (the “Registration Statement”), and to the references made to our firm and such opinion in the Registration Statement. Notwithstanding the foregoing, in giving such consent, we do not admit and we hereby disclaim that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do we hereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term “experts” as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

 

Very truly yours,

 

/s/ Mohit Pareek

 

Gemini Valuation Services

 

 C: 
   

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-4/A’ Filing    Date    Other Filings
Filed on:8/12/2010-K/A,  8-K,  CORRESP
8/7/20
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/06/21  Enveric Biosciences, Inc.         8-K:1,2,3,512/30/20   13:1M                                     M2 Compliance LLC/FA
11/10/20  Enveric Biosciences, Inc.         S-4/A                121:18M                                    M2 Compliance LLC/FA
11/09/20  Enveric Biosciences, Inc.         S-4/A                122:18M                                    M2 Compliance LLC/FA
10/22/20  Enveric Biosciences, Inc.         S-4/A                123:18M                                    M2 Compliance LLC/FA
 9/17/20  Enveric Biosciences, Inc.         S-4/A       9/16/20  118:18M                                    M2 Compliance LLC/FA


20 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/28/20  Enveric Biosciences, Inc.         S-4         5/27/20   98:16M                                    M2 Compliance LLC/FA
 5/06/20  Enveric Biosciences, Inc.         8-K:1,2,3,9 5/06/20    6:372K                                   Broadridge Fin’l So… Inc
 3/04/20  Enveric Biosciences, Inc.         8-K:1,2,9   2/27/20    3:91K                                    Broadridge Fin’l So… Inc
 1/13/20  Enveric Biosciences, Inc.         8-K:1,3,8,9 1/10/20    9:2M                                     Broadridge Fin’l So… Inc
11/25/19  Enveric Biosciences, Inc.         8-K:1,2,9  11/25/19    3:297K                                   Broadridge Fin’l So… Inc
 8/14/19  Enveric Biosciences, Inc.         S-3                    5:1.1M                                   Broadridge Fin’l So… Inc
 3/26/19  Enveric Biosciences, Inc.         10-K       12/31/18   73:7.1M                                   Broadridge Fin’l So… Inc
 1/25/19  Enveric Biosciences, Inc.         8-K:1,2,9   1/23/19    6:465K                                   Broadridge Fin’l So… Inc
12/14/18  Enveric Biosciences, Inc.         8-K:3,5,9  12/10/18    3:97K                                    Broadridge Fin’l So… Inc
10/17/18  Enveric Biosciences, Inc.         8-K:1,5,9  10/16/18    3:78K                                    Olshan Frome Wolosky LLP
 8/17/18  Enveric Biosciences, Inc.         8-K:1,3,5,8 8/16/18    5:254K                                   Olshan Frome Wolosky LLP
 7/30/18  Enveric Biosciences, Inc.         8-K:1,3,8,9 7/25/18    6:613K                                   Olshan Frome Wolosky LLP
 6/26/18  Enveric Biosciences, Inc.         8-K:1,9     6/22/18    3:282K                                   Olshan Frome Wolosky LLP
 3/02/18  Enveric Biosciences, Inc.         8-K:1,9     2/28/18    2:37K                                    Olshan Frome Wolosky LLP
 3/08/17  Enveric Biosciences, Inc.         8-K:1,3,9   3/02/17    4:169K                                   Olshan Frome Wolosky LLP
 1/04/17  Enveric Biosciences, Inc.         8-K:1,3,5,912/30/16    3:146K                                   Olshan Frome Wolosky LLP
 6/23/16  Enveric Biosciences, Inc.         8-K:5,9     6/21/16    3:254K                                   Olshan Frome Wolosky LLP
12/17/15  Enveric Biosciences, Inc.         S-8        12/17/15    4:480K                                   Olshan Frome Wolosky LLP
11/23/15  Enveric Biosciences, Inc.         10-Q        9/30/15   32:1.3M                                   Edgar.Tech Fili… Svcs/FA
 6/01/15  Enveric Biosciences, Inc.         8-K:1,2,3,4 5/26/15   15:1.9M                                   Olshan Frome Wolosky LLP
Top
Filing Submission 0001493152-20-015374   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 5:59:12.2am ET